Skip to main content

Advertisement

SpringerLink
Log in

Impact of hypoxia in head and neck cancer radiotherapy

  • Expert Review
  • Published:
Clinical and Translational Imaging Aims and scope Submit manuscript

Abstract

Background

Radiotherapy plays an important role in the treatment of pharyngo-laryngeal and oral cavity head and neck squamous cell carcinoma (HNSCC) either as single modality, in combination with concomitant chemotherapy or epithermal growth factor inhibitor, or as adjuvant treatment after curative surgery. Various biological factors have been shown to impact on tumour response to radiotherapy, and among them tumour hypoxia.

Aim

This article reviews the clinical data on measurement of tumour hypoxia and summarizes the various options to counteract it, with a special emphasis on the use of hypoxic cell radiosensitizers, radiation dose escalation, and the proper selection of patients who may benefit from such therapeutic interventions.

Results

It has been shown that up to 25% of HNSCC express pO2 value below 2.5 mm Hg, and modification of tumour hypoxia has been demonstrated to improve loco-regional control and overall survival. In particular, the concomitant use of nimorazole, a hypoxic cell radiosensitizer, has been demonstrated in a seminal DAHANCA trial to significantly improve outcome in patients with head and neck SCC. More recently, among the patients included into this trial, a 15-gene hypoxia classifier indicated that only those patients with hypoxic tumours benefited from the combined radiotherapy and nimorazole treatment.

Conclusions

An ongoing trial is validating both the use of nimorazole and the gene classifier for patients treated with concomitant chemo-radiotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD (2017) NCCN, guidelines insights: head and neck cancers, Version 2.2017. J Natl Compr Cancer Netw 15(6):761–770

    Article  Google Scholar 

  2. Gatta G, Botta L, Sánchez MJ, Anderson LA, Pierannunzio D, Licitra L, EUROCARE Working Group (2015) Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: the EUROCARE-5 population-based study. Eur J Cancer 51(15):2130–2143

    Article  PubMed  Google Scholar 

  3. Huang SH, Xu W, Waldron J, Siu L, Shen X, Tong L, Ringash J, Bayley A, Kim J, Hope A, Cho J, Giuliani M, Hansen A, Irish J, Gilbert R, Gullane P, Perez-Ordonez B, Weinreb I, Liu FF, O’Sullivan B (2015) Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol 33(8):836–845

    Article  PubMed  Google Scholar 

  4. Overgaard J, Jovanovic A, Godballe C, Grau Eriksen J (2016) The Danish head and neck cancer database. Clin Epidemiol 25(8):491–496

    Article  Google Scholar 

  5. Grégoire V, Langendijk JA, Nuyts S (2015) Advances in radiotherapy for head and neck cancer. J Clin Oncol 33(29):3277–3284

    Article  PubMed  Google Scholar 

  6. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578

    Article  CAS  PubMed  Google Scholar 

  7. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maître A, Pajak TF, Poulsen MG, O’Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP, Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 368(9538):843–854 (Review)

    Article  PubMed  Google Scholar 

  8. Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14

    Article  PubMed  Google Scholar 

  9. Vaupel P (2004) Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14:198–206

    Article  PubMed  Google Scholar 

  10. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58(7):1408–1416 (Review)

    CAS  PubMed  Google Scholar 

  11. Vaupel P, Höckel M, Mayer A (2007) Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 9(8):1221–1235 (Review)

    Article  CAS  PubMed  Google Scholar 

  12. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J (2012) Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 9(12):674–687

    Article  CAS  PubMed  Google Scholar 

  13. Nordsmark M, Bentzen SM, Rudat V et al (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77:18–24

    Article  PubMed  Google Scholar 

  14. Overgaard J (2011) Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck–a systematic review and meta-analysis. Radiother Oncol 100(1):22–32

    Article  PubMed  Google Scholar 

  15. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindeløv B, Jørgensen K (1998) A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46(2):135–146

    Article  CAS  PubMed  Google Scholar 

  16. Toustrup K, Sørensen BS, Lassen P, Wiuf C, Alsner J, Overgaard J, Danish Head and Neck Cancer Group (DAHANCA) (2012) Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 102(1):122–129

    Article  CAS  PubMed  Google Scholar 

  17. Bassler N, Toftegaard J, Luhr A, Sorensen BS, Scifoni E, Kramer M et al (2014) LET-painting increases tumour control probability in hypoxic tumours. Acta Oncol 53(1):25–32

    Article  PubMed  Google Scholar 

  18. Thorwarth D, Alber M (2010) Implementation of hypoxia imaging into treatment planning and delivery. Radiother Oncol 97(2):172–175

    Article  PubMed  Google Scholar 

  19. Bentzen SM, Gregoire V (2011) Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol 21(2):101–110

    Article  PubMed  PubMed Central  Google Scholar 

  20. Geets X, Gregoire V, Lee JA (2013) Implementation of hypoxia PET imaging in radiation therapy planning. Q J Nucl Med Mol Imaging 57(3):271–282

    CAS  PubMed  Google Scholar 

  21. Nordsmark M, Bentzen SM, Overgaard J (1994) Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity. Acta Oncol 33(4):383–389

    Article  CAS  PubMed  Google Scholar 

  22. Raleigh JA, Chou SC, Arteel GE, Horsman MR (1999) Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 151(5):580–589

    Article  CAS  PubMed  Google Scholar 

  23. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, de Wilde PC, Bussink J, Raleigh JA, van der Kogel AJ (2002) Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62(23):7066–7074

    CAS  PubMed  Google Scholar 

  24. Nordsmark M, Loncaster J, Aquino-Parsons C, Chou SC, Gebski V, West C, Lindegaard JC, Havsteen H, Davidson SE, Hunter R, Raleigh JA, Overgaard J (2006) The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother Oncol 80(2):123–131

    Article  CAS  PubMed  Google Scholar 

  25. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721–732

    Article  CAS  PubMed  Google Scholar 

  26. Loncaster JA, Harris AL, Davidson SE et al (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61:6394–6399

    CAS  PubMed  Google Scholar 

  27. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I, West C (2001) Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7(4):928–934

    CAS  PubMed  Google Scholar 

  28. Bussink J, Kaanders JH, van der Kogel AJ (2003) Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 67(1):3–15

    Article  PubMed  Google Scholar 

  29. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9(1):59–67

    CAS  PubMed  Google Scholar 

  30. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR, Danish Head and Neck Cancer Study Group (2005) Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6(10):757–764

    Article  CAS  PubMed  Google Scholar 

  31. Petrik D, Lavori PW, Cao H, Zhu Y, Wong P, Christofferson E, Kaplan MJ, Pinto HA, Sutphin P, Koong AC, Giaccia AJ, Le QT (2006) Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol 24(33):5291–5297

    Article  CAS  PubMed  Google Scholar 

  32. Snitcovsky I, Leitão GM, Pasini FS, Brunialti KC, Mangone FR, Maistro S, de Castro G, Jr Villar RC, Federico MH (2009) Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy. Arch Otolaryngol Head Neck Surg 135(8):807–811

    Article  PubMed  Google Scholar 

  33. Lapi SE, Voller TF, Welch MJ (2009) Positron emission tomography imaging of hypoxia. PET Clin 4(1):39–47

    Article  PubMed  PubMed Central  Google Scholar 

  34. Lehtio K, Oikonen V, Nyman S, Gronroos T, Roivainen A, Eskola O et al (2003) Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging 30(1):101–108

    Article  PubMed  Google Scholar 

  35. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P et al (2005) Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 46(1):106–113

    PubMed  Google Scholar 

  36. Mahy P, Geets X, Lonneux M, Levêque P, Christian N, De Bast M, Gillart J, Labar D, Lee J, Grégoire V (2008) Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism. Eur J Nucl Med Mol Imaging 35(7):1282–1289

    Article  CAS  PubMed  Google Scholar 

  37. Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, Alsner J, Sørensen BS, Toustrup K, Jakobsen S, Petersen J, Petersen H, Theil J, Nordsmark M, Overgaard J (2012) FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol 105(1):14–20

    Article  PubMed  Google Scholar 

  38. Zips D, Zöphel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, Appold S, Steinbach J, Kotzerke J, Baumann M (2012) Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 105(1):21–28

    Article  PubMed  Google Scholar 

  39. Nielsen T, Wittenborn T, Horsman MR (2012) Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in preclinical studies of antivascular treatments. Pharmaceutics 4(4):563–589

    Article  PubMed  PubMed Central  Google Scholar 

  40. Simoncic U, Leibfarth S, Welz S, Schwenzer N, Schmidt H, Reischl G, Pfannenberg C, Fougère C, Nikolaou K, Zips D, Thorwarth D (2017) Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patients. Med Phys 44(6):2358–2368

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Adams GE, Stratford IJ, Bremner JC, Edwards HS, Fielden EM (1991) Nitroheterocyclic compounds as radiation sensitizers and bioreductive drugs. Radiother Oncol 20(Suppl 1):85–91

    Article  CAS  PubMed  Google Scholar 

  42. MRC working party on misonidazole in head and neck cancer (1984) A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of head and neck cancer. Br J Radiol 57:585–595

    Article  Google Scholar 

  43. Fazekas J, Pajak TF, Wasserman T et al (1987) Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III–IV squamous cancers of the head and neck. Int J Radiat Oncol Biol Phys 13:1155–1160

    Article  CAS  PubMed  Google Scholar 

  44. Lee DJ, Pajak TF, Stetz J, Order SE, Weissberg JB, Fischer JJ (1989) A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04). Int J Radiat Oncol Biol Phys 16:465–470

    Article  CAS  PubMed  Google Scholar 

  45. Overgaard J, Hansen HS, Andersen AP, Hjelm-Hansen M, Jørgensen K, Sandberg E, Berthelsen A, Hammer R, Pedersen M (1989) Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 16(4):1065–1068

    Article  CAS  PubMed  Google Scholar 

  46. Timothy AR, Overgaard J, Overgaard M (1984) A phase I clinical study of nimorazole as a hypoxic radiosensitizer. Int J Radiat Oncol Biol Phys 10:1765–1768

    Article  CAS  PubMed  Google Scholar 

  47. Metwally MA, Frederiksen KD, Overgaard J (2014) Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol 53(5):654–661

    Article  CAS  PubMed  Google Scholar 

  48. Thomson D, Yang H, Baines H, Miles E, Bolton S, West C, Slevin N (2014) NIMRAD—a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. Clin Oncol 26(6):344–347

    Article  CAS  Google Scholar 

  49. Kaanders JH, Bussink J, van der Kogel AJ (2002) ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 3(12):728–737 (Review)

    Article  PubMed  Google Scholar 

  50. Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, Chin A, Marres HA, de Bree R, van der Kogel AJ, Hoogsteen IJ, Bussink J, Span PN, Kaanders JH (2012) Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 30(15):1777–1783

    Article  CAS  PubMed  Google Scholar 

  51. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, Koutcher JA (2000) Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47:551–560

    Article  CAS  PubMed  Google Scholar 

  52. Thorwarth D, Eschmann SM, Paulsen F, Alber M (2007) Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys 68:291–300

    Article  PubMed  Google Scholar 

  53. Toma-Dasu I, Uhrdin J, Antonovic L, Dasu A, Nuyts S, Dirix P, Haustermans K, Brahme A (2012) Dose prescription and treatment planning based on FMISO-PET hypoxia. Acta Oncol 51(2):222–230

    Article  PubMed  Google Scholar 

  54. Chang JH, Wada M, Anderson NJ, Lim Joon D, Lee ST, Gong SJ, Gunawardana DH, Sachinidis J, O’Keefe G, Gan HK, Khoo V, Scott AM (2013) Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study. Acta Oncol 52(8):1723–1729

    Article  CAS  PubMed  Google Scholar 

  55. Henriques de Figueiredo B, Zacharatou C, Galland-Girodet S, Benech J, De Clermont-Gallerande H, Lamare F, Hatt M, Digue L, Mones De, del Pujol E, Fernandez P (2015) Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers. Strahlenther Onkol 191(3):217–224

    Article  CAS  PubMed  Google Scholar 

  56. Servagi-Vernat S, Differding S, Sterpin E, Hanin FX, Labar D, Bol A, Lee JA, Gregoire V (2015) Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study. Acta Oncol 54:1008–1016

    Article  CAS  PubMed  Google Scholar 

  57. Walrand S, Hesse M, Jamar F (2016) Update on novel trends in PET/CT technology and its clinical applications. Br J Radiol 89:20160534

    Article  Google Scholar 

  58. Lee JA (2010) Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology. Radiother Oncol 96(3):302–307

    Article  PubMed  Google Scholar 

  59. Servagi-Vernat S, Differding S, Hanin FX, Labar D, Bol A, Lee JA, Gregoire V (2014) A prospective clinical study of (1)(8)F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. Eur J Nucl Med Mol Imaging 41:1544–1552

    Article  CAS  PubMed  Google Scholar 

  60. Bollineni VR, Koole MJ, Pruim J, Brouwer CL, Wiegman EM, Groen HJ, Vlasman R, Halmos GB, Oosting SF, Langendijk JA, Widder J, Steenbakkers RJ (2014) Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies. Radiother Oncol 113(2):198–203

    Article  PubMed  Google Scholar 

  61. Welz S, Mönnich D, Pfannenberg C, Nikolaou K, Reimold M, La Fougère C, Reischl G, Mauz PS, Paulsen F, Alber M, Belka C, Zips D, Thorwarth D (2017) Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. Radiother Oncol. doi:10.1016/j.radonc.2017.04.004

    Google Scholar 

  62. Toustrup K, Sørensen BS, Nordsmark M, Busk M, Wiuf C, Alsner J, Overgaard J (2011) Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res 71(17):5923–5931

    Article  CAS  PubMed  Google Scholar 

  63. Toustrup K, Sørensen BS, Metwally MA, Tramm T, Mortensen LS, Overgaard J, Alsner J (2016) Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials. Acta Oncol 55(9–10):1091–1098

    Article  CAS  PubMed  Google Scholar 

  64. Sørensen BS, Busk M, Olthof N, Speel EJ, Horsman MR, Alsner J, Overgaard J (2013) Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells. Radiother Oncol 108(3):500–505

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, St-Luc University Hospital, Woluwe-Saint-Lambert, Belgium

    Vincent Grégoire

  2. Molecular Imaging, Radiotherapy and Oncology unit, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium

    Vincent Grégoire

  3. Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark

    Jesper Eriksen

  4. Radiation Oncology Department, Cliniques Universitaires St-Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium

    Vincent Grégoire

Authors
  1. Vincent Grégoire
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jesper Eriksen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

V. Grégoire and J. Eriksen: content planning, writing, and editing.

Corresponding author

Correspondence to Vincent Grégoire.

Ethics declarations

Conflict of interest

V. Grégoire and J. Eriksen declare no conflict of interest.

Ethical approval

This article does not contain any studies with human or animal subjects performed by the any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grégoire, V., Eriksen, J. Impact of hypoxia in head and neck cancer radiotherapy. Clin Transl Imaging 5, 497–505 (2017). https://doi.org/10.1007/s40336-017-0252-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40336-017-0252-9

Keywords

Search

Navigation